Hemoglobin adducts ofthe carcinogenic tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) release 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) upon mild base or acid hydrolysis. HPB has been detected in hydrolysates of hemoglobin from smokers and snuff dippers and has been proposed as a dosimeter of exposure to and metabolic activation ofNNK in people exposed to tobacco products. In this study, labeling experiments were carried out with ["'O]NaOH that provide strong evidence that the globin adduct that releases HPB upon hydrolysis is a carboxylic ester. Globin was isolated from rats treated with [5-3HINNK. This globin was reacted with NaCNBH3, folowed by hydrolysis at room temperature with 02 N NaOH. Analysis of the products demonstrated the presence of 4-hydroxy-1-(3-pyridyl)-1-butanol, but not HPB. These results demonstrate that the adduct in globin has a free carbonyl group and is not a Schiff base. This sequence of reactions was then carried out with [1OJNaOH under conditions that were shown to result in incorporation of "SO if nucleophilic displacement at C4 had occurred. Analysis by GC-MS of the 4-hydroxy-l-(3-pyridyl)-1-butanol formed in this experiment demonstrated that there was no incorporation of "O These results are consistent only with the hydrolysis of an ester by a BAc2 mechanism. Therefore, the adduct releasing HPB upon mild base hydrolysis must be a 4-(3-pyridyl)-4oxobutyl ester of aspartate, glutamate, or a terminal carboxylate. Futher support for this conclusion was obtained by investigating the chemistry of a model ester, a-methyl-3-4-(3-pyridyl)-4-xobutyl-N-carbobenzyloxy-L-aspartate. The hydrolysis properties of this compound were similar to those ofthe HPBreleasing henwglobin adduct.
Introduction
When rats or mice are treated with the carcinogenic tobaccospecific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), hemoglobin adducts are formed (1) (2) (3) . Mild base hydrolysis ofthis hemoglobin releases 20-40% ofthe bound material as 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB). Release of HPB from human hemoglobin has been suggested as a dosimeter of human exposure to, and metabolic activation of, NNK as well as a related nitrosamine, N'-nitrosonomicotine. Levels of HPB released from hemoglobin have been quantified in humans by GC-MS (4) . Figure 1 illustrates the postulated mechanism of NNKhemoglobin adduct formation. Enzymatic hydroxylation of the methyl carbon yields a-hydroxymethyl-NNK (compound 3 in Fig. 1 ), which is unstable and spontaneously decomnposes to formaldehyde and 4-(3-pyridyl)-4-oxobutyl diazohydroxide (com-pound 4 in Fig. 1 ). This intermediate reacts with a nucleophilic site in hemoglobin to produce an adduct that releases HPB upon hydrolysis with NaOH or HCl under mild conditions. Previous studies have provided support for this mechanism. These studies have shown that the adduct is covalently bound to globin (3). a-Acetoxy-NNK (NNKOAc; compound 2 in Fig. 1 ), a stable precursor to a-hydroxymethyl-NNK, formed the same adduct upon injection into mice (3). In contrast, HPB did not react with hemoglobin in vitro and did not produce HPB-releasing hemoglobin adducts when injected into mice (3) .
An earlier study showed that cysteine is not a site ofadduct formation in the hemoglobin of rats treated with NNK (5) . In this paper, we describe experiments with [180] NaOH that strongly support the hypothesis that the HPB-releasing hemoglobin adduct is a carboxylic ester.
Results and Discussion
Our initial goal was to determine whether or not the adduct had a free carbonyl group. The cyclic intermediate (compound 6 in Fig. 2 Fig. 2 ) and the tosylate (compound 9 in Fig. 2 ). Compound 8 (Fig. 2) was a model for a carboxylic ester adduct. As expected, hydrolysis ofthis compound with ['80 ]NaOH yielded compound 7 (Fig. 2) , with an M+1 peak of 168 (relative intensity, 100) in its chemical ionization-MS; no peak at m/e 170 was detected. Thus, there was no incorporation of label into the diol (compound 7 in Fig. 2 ). Compound 9 (Fig. 2) was a model for adducts that would have undergone a nucleophilic substitution reaction resulting in incorporation of 180. Hydrolysis with ['8O]NaOH produced mainly 3-vinylpyridine (95 %). The minor product (compound 10 in Fig.  2 ) contained > 85 % 80. We also attempted to prepare hydroxy tosylate (compound 11 in Fig. 2) as a model, but it was unstable and its solvolysis produced exclusively the furan (compound 12 in Fig. 2 ). These control experiments established that our conditions were adequate to detect incorporation of ISO upon hydrolysis of the globin adduct.
Globin from rats treated with [5-3H] Fig. 2) . Hydrolysis was carried out under mild basic or acidic conditions. Release of HPB was complete in base, whereas only 6% was released in acid. The release of HPB from globin of NNK-treated rats under the same hydrolysis conditions was complete in base, accounting for 19.6% of the radioactivity bound to globin. In acid, only 2.3 % of the bound radioactivity was released as HPB (5); thus, the extent of hydrolysis was 12 % as great as that observed in base.
The carboxylic ester adduct ofNNK in globin could be formed by reaction ofdiazohydroxide (compound 4 in Fig. 1 ) with aspartate, glutamate, or the terminal carboxyl groups ofglobin. A recent study has used l-amino-2,3-propanediol to locate one ofthe benzo[a]pyrene diol epoxide carboxylic ester adducts at aspartate 47 ofthe (x chain ofhuman hemoglobin (7). We are currently exploring this approach for identifying the acids involved in formation of the HPB-releasing adduct.
